Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

In-depth multimodal validation of <sup>18</sup>F-THK5351 for imaging monoamine oxidase-B-mediated reactive astrogliosis in Alzheimer's and related neurodegenerative diseases.

Experimental & molecular medicine·2026
Same author

Astrocyte reactivity across the AD continuum measured by [<sup>18</sup>F]SMBT-1 and its relationship with the Aβ burden.

European journal of nuclear medicine and molecular imaging·2026
Same author

Biomarkers.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Whole-body biodistribution of [<sup>18</sup>F]SMBT-1: a novel PET tracer for monoamine oxidase B imaging in healthy humans.

Annals of nuclear medicine·2026
Same author

Basic Science and Pathogenesis.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Automated radiosynthesis and clinical experience of [<sup>18</sup>F]SMBT-1 PET imaging for <i>in vivo</i> evaluation of reactive astrocyte in Parkinson's disease: a pilot study.

Frontiers in nuclear medicine·2025
Same journal

Unveiling the procoagulant state in Alzheimer's disease: A novel PET imaging strategy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Estimated labor market outcomes of people progressing from preclinical to early-stage Alzheimer's disease in the United States.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Amyloid exacerbates tau and alpha-synuclein pathologies, behavioral impairments, and neuroinflammation in a mixed dementia model.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
See all related articles

Related Experiment Video

Updated: Apr 28, 2026

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

1.1K

In vivo tau imaging: obstacles and progress.

Victor L Villemagne1, Nobuyuki Okamura2

  • 1Department of Nuclear Medicine and Centre for PET, Austin Health, Melbourne, VIC, Australia; The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Melbourne, VIC, Australia.

Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|June 14, 2014
PubMed
Summary
This summary is machine-generated.

New imaging agents target tau protein accumulation, a key factor in traumatic brain injury and neurodegenerative diseases like Alzheimer's. This research aids in understanding and treating these conditions in both military and civilian populations.

Keywords:
Alzheimer's diseaseChronic traumatic encephalopathyMolecular neuroimagingNeurodegenerationRadiotracer designTauTauopathies

More Related Videos

Longitudinal In Vivo Imaging of the Cerebrovasculature: Relevance to CNS Diseases
07:47

Longitudinal In Vivo Imaging of the Cerebrovasculature: Relevance to CNS Diseases

Published on: December 6, 2016

6.8K
In Vivo Microdialysis Method to Collect Large Extracellular Proteins from Brain Interstitial Fluid with High-molecular Weight Cut-off Probes
08:17

In Vivo Microdialysis Method to Collect Large Extracellular Proteins from Brain Interstitial Fluid with High-molecular Weight Cut-off Probes

Published on: September 26, 2018

14.3K

Related Experiment Videos

Last Updated: Apr 28, 2026

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

1.1K
Longitudinal In Vivo Imaging of the Cerebrovasculature: Relevance to CNS Diseases
07:47

Longitudinal In Vivo Imaging of the Cerebrovasculature: Relevance to CNS Diseases

Published on: December 6, 2016

6.8K
In Vivo Microdialysis Method to Collect Large Extracellular Proteins from Brain Interstitial Fluid with High-molecular Weight Cut-off Probes
08:17

In Vivo Microdialysis Method to Collect Large Extracellular Proteins from Brain Interstitial Fluid with High-molecular Weight Cut-off Probes

Published on: September 26, 2018

14.3K

Area of Science:

  • Neuroscience
  • Radiochemistry
  • Medical Imaging

Background:

  • Traumatic brain injury (TBI) is a significant concern, particularly in military personnel, with links to tau aggregate accumulation.
  • Tau pathology is a recognized risk factor in neurodegenerative conditions, including Alzheimer's disease (AD) and frontotemporal lobar degeneration (FTLD).
  • Understanding tau's role is crucial for developing effective diagnostics and therapeutics for TBI, chronic traumatic encephalopathy (CTE), and dementias.

Purpose of the Study:

  • To develop selective tau ligands for in vivo imaging of tau pathology.
  • To facilitate research into the physiopathologic mechanisms of TBI and CTE.
  • To enable new insights into tau pathology in the human brain for improved diagnosis and treatment strategies.

Main Methods:

  • Development of novel radiotracers designed for selective binding to tau aggregates.
  • Focus on overcoming challenges in tau aggregation and radiotracer design for in vivo applications.
  • Utilizing advanced imaging techniques for noninvasive assessment of tau pathology.

Main Results:

  • Significant progress has been made in developing selective tau imaging agents.
  • These tracers enable noninvasive assessment of the extent and changes in tau pathology over time.
  • Potential to correlate tau pathology with cognitive performance and other biomarkers.

Conclusions:

  • Selective tau imaging agents are crucial for advancing research in TBI, CTE, and neurodegenerative dementias.
  • These tools will facilitate a deeper understanding of tau's role in disease.
  • The development supports improved diagnosis, monitoring, and therapeutic trial assessment for tauopathies.